Good thread. I agree time is of the essence in bio and Dr. Kim seems to be caught up in other things. Just doesn't appear to be focused. This Peer Review is doing more harm than good.
It's a joke, it's management funnin' the retail boys. It's their little game. You will get used to it here, it is like a club. Dr. Kim is akin to an oriental Mickey Rooney. You know, hey gang I have a lab, let's put on a mice show. Kinda keeps things from getting too serious.
How can you assume that? Every time he buys he seems to come right back and dilutes again. The market knows how he works and the last one at $8 slammed us hard. Who would of thought the discount would be at $8. He has to hire a business oriented person and pay attention to where the Peer Review is and partnerships. He has lost all momentum. Looking for news for the CC, but know there won't be anything we don't already know.
THis has nothing to do with weak hands, this execution is brutal. Peer Review, loss of half of big pharma partnership, RS and shelf offerings, and no data to boost our pps or put in a floor. Nothing by Dr. Kim buying shares to calm investors. He just doesn't get it. He may be a great scientist, but the rest of the equation is terrible, although Bernie will tell you everything is fine.
That the good Dr. bought $2M in shares to try to stop the tumble? What does he know that we don't? Is the fuse light again this year? Seems awful familiar.
Doesn't seem so trivial to me, but I hope you are right. Just looks like he has set the bar very low for anyone coming to the table and that is very distasteful to me.
And I suspect you are correct. This guy has always come up short so where is the surprise. Years ahead of everybody else, best tech there is right now, and a real bubble buster. Was he in over his head negotiating with the best? Appears they took his lunch money and sent him home crying. No choice but to see where it goes and how much market share we can get as the only option for embedded right now. Of course we haven't seen embedded in anything yet.
My question at this point is what has that done to the value of the company? Why buy the cow when the milk is free? And if it is free for Sony, who is going to pay more? A lot of implications yet to be totally understood. Come on Lenovo and fire another shot.
As a footnote, I was always wary that Tokman was going to show his skills in his negotiations with Sony as this is the big leagues now, and I was worried they would eat his lunch. Hate to see this margin issue, but you have to walk a mile in his shoes to understand the whole story. The guy is an unproven commodity for me.
I would like to think so, but 6 years of knowing Alec Tokman makes that a very small likelihood. This on the surface ranks right up there with "First and Goal" way back in 2010, and "No gating issues" just after that. I was looking for some forward guidance in the form of break even in the coming months, and now I understand that is not going to happen for awhile. I and others are now looking for institutional interest going forward from here. If they increase, that will be my tell. If Tokman can't generate any interest in the coming months then they see what we are seeing. They examine a company a lot better than we retail investors do and they are the best barometer for me.